mRNA Tech Transfer Phase 2.0 Discussed at G20 Summit
The Pharma Data
JUNE 13, 2025
2026–2030). Importantly, this will enable them to produce mRNA vaccines during periods between health crises, retaining trained personnel, technical expertise, and production capacity while retaining the ability to respond quickly in the event of future disease outbreaks.
Let's personalize your content